VIP inhibits Porphyromonas gingivalis LPS-induced immune responses in human monocytes

Journal of Dental Research

Volumn 84, Issue 11, 2005, Pages 999-1004

  Foster, N ^a   Cheetham, J ^a   Taylor, J J ^a   Preshaw, P M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

LPS; Monocyte; Porphyromonas gingivalis; VIP

Indexed keywords

AUTACOID; CD14 ANTIGEN; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; LIPOPOLYSACCHARIDE; PROTEIN C JUN; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; CELL CULTURE; CONFOCAL MICROSCOPY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; MONOCYTE; PORPHYROMONAS GINGIVALIS; TH1 CELL; TIME;

ANTIGENS, CD14; CELLS, CULTURED; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MICROSCOPY, CONFOCAL; MONOCYTES; NF-KAPPA B; PORPHYROMONAS GINGIVALIS; PROTO-ONCOGENE PROTEINS C-JUN; TH1 CELLS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VASOACTIVE INTESTINAL PEPTIDE;

EID: 33644655656     PISSN: 00220345     EISSN: None     Source Type: Journal    
DOI: 10.1177/154405910508401106     Document Type: Article

References (28)

1. Darveau RP, Pham TT, Lemley K, Reife RA, Bainbridge BW, Coats SR, et al. (2004). Porphyromonas gingivalis lipopolysaccharide contains multiple lipid A species that functionally interact with both toll-like receptors 2 and 4. Infect Immun 72:5041-5051.
2. Delgado M, Ganea D (2000). Inhibition of IFN-gamma-induced Janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J Immunol 165:3051-3057.
3. Delgado M, Ganea D (2003). Vasoactive intestinal peptide inhibits IL-8 production in human monocytes by downregulating nuclear factor kappaB-dependent transcriptional activity. Biochem Biophys Res Commun 302:275-283.
4. Delgado M, Leceta J, Abad C, Martinez C, Ganea D, Gomariz RP (1999a). Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide. J Neuroimmunol 99:61-71.
5. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D (1999b). Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol 162:1707-1716.
6. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D (1999c). VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J Neuroimmunol 96:167-181.
7. Delgado M, Pozo D, Martinez C, Leceta J, Calvo JR, Ganea D, et al. (1999d). Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies. J Immunol 162:2358-2367.
8. Dixon DR, Bainbridge BW, Darveau RP (2004). Modulation of the innate immune response within the periodontium. Periodontol 2000 35:53-74.
9. Duncan L, Yoshioka M, Chandad F, Grenier D (2004). Loss of lipopolysaccharide receptor CD14 from the surface of human macrophage-like cells mediated by Porphyromonas gingivalis outer membrane vesicles. Microb Pathog 36:319-325.
10. Foster N, Hulme SD, Barrow PA (2003). Induction of antimicrobial pathways during early-phase immune response to Salmonella spp. in murine macrophages: gamma interferon (IFN-gamma) and upregulation of IFN-gamma receptor alpha expression are required for NADPH phagocytic oxidase gp91-stimulated oxidative burst and control of virulent Salmonella spp. Infect Immun 71:4733-4741.
11. Foster N, Hulme SD, Barrow PA (2005). Inhibition of IFN-gamma-stimulated proinflammatory cytokines by vasoactive intestinal peptide (VIP) correlates with increased survival of Salmonella enterica serovar typhimurium phoP in murine macrophages. J Interferon Cytokine Res 25:31-42.
12. Ganea D, Rodriguez R, Delgado M (2003). Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity. Cell Mol Biol 49:127-142.
13. Graves DT, Cochran D (2003). The contribution of interleukin-1 and tumor necrosis factor to periodontal tissue destruction. J Periodontol 74:391-401.
14. Jotwani R, Pulendran B, Agrawal S, Cutler CW (2003). Human dendritic cells respond to Porphyromonas gingivalis LPS by promoting a Th2 effector response in vitro. Eur J Immunol 33:2980-2986.
15. Kitchens RL, Ulevitch RJ, Munford RS (1992). Lipopolysaccharide (LPS) partial structures inhibit responses to LPS in a human macrophage cell line without inhibiting LPS uptake by a CD14-mediated pathway. J Exp Med 176:485-494.
16. Lamont RJ, Jenkinson HF (1998). Life below the gum line: pathogenic mechanisms of Porphyromonas gingivalis. Microbiol Mol Biol Rev 62:1244-1263.
17. Leceta J, Martinez C, Delgado M, Garrido E, Gomariz RP (1996). Expression of vasoactive intestinal peptide in lymphocytes: a possible endogenous role in the regulation of the immune system. Adv Neuroimmunol 6:29-36.
18. Lindemann RA, Economou JS, Rothermel H (1988). Production of interleukin-1 and tumor necrosis factor by human peripheral monocytes activated by periodontal bacteria and extracted lipopolysaccharides. J Dent Res 67:1131-1135.
19. Linden GJ, Mullally BH, Burden DJ, Lamey PJ, Shaw C, Ardill J, et al. (2002). Changes in vasoactive intestinal peptide in gingival crevicular fluid in response to periodontal treatment. J Clin Periodontol 29:484-489.
20. Liu H, Sidiropoulos P, Song G, Pagliari LJ, Birrer MJ, Stein B, et al. (2000). TNF-alpha gene expression in macrophages: regulation by NF-kappa B is independent of c-Jun or C/EBP beta. J Immunol 164:4277-4285.
21. McFarlane CG, Reynolds JJ, Meikle MC (1990). The release of interleukin-1 beta, tumor necrosis factor-alpha and interferon-gamma by cultured peripheral blood mononuclear cells from patients with periodontitis. J Periodontal Res 25:207-214.
22. Nagasawa T, Kobayashi H, Aramaki M, Kiji M, Oda S, Izumi Y (2004). Expression of CD14, CD16 and CD45RA on monocytes from periodontitis patients. J Periodontal Res 39:72-78.
23. Ogawa T (1993). Chemical structure of lipid A from Porphyromonas (Bacteroides) gingivalis lipopolysaccharide. FEBS Lett 332:197-201.
24. Paquette DW, Williams RC (2000). Modulation of host inflammatory mediators as a treatment strategy for periodontal diseases. Periodontol 2000 24:239-252.
25. Pulendran B, Kumar P, Cutler CW, Mohamadzadeh M, Van Dyke T, Banchereau J (2001). Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J Immunol 167:5067-5076.
26. Rossomando EF, Kennedy JE, Hadjimichael J (1990). Tumour necrosis factor alpha in gingival crevicular fluid as a possible indicator of periodontal disease in humans. Arch Oral Biol 35:431-434.
27. Xin Z, Sriram S (1998). Vasoactive intestinal peptide inhibits IL-12 and nitric oxide production in murine macrophages. J Neuroimmunol 89:206-212.
28. Zhou Q, Desta T, Fenton M, Graves DT, Amar S (2005). Cytokine profiling of macrophages exposed to Porphyromonas gingivalis, its lipopolysaccharide, or its FimA protein. Infect Immun 73:935-943.